Lichen Simplex Chronicus (Investigational Adjunct)
Investigational adjunct for lichen simplex chronicus; breaking the itch-scratch cycle with potent topical corticosteroids, occlusion, topical calcineurin inhibitors, and treatment of underlying pruritus etiology remain evidence-based.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for lichen simplex chronicus. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). No controlled trials. Evidence-based first-line management is breaking the scratch-itch cycle with potent topical corticosteroid (often under occlusion), antihistamines to reduce nighttime itch and scratching, identifying and treating triggers (atopic dermatitis, psoriasis, anxiety, contact allergens), gabapentin or SSRI for psychogenic itch, and behavioral approaches such as habit-reversal training.
- Riesgos principales
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- New bite sites may become additional scratch targets
- Worsening of the scratch-itch cycle from cutaneous inflammation
- Quién no debería considerar esto
- Patients who have not tried potent topical corticosteroid under occlusion
- Patients with possible underlying psoriasis, atopic dermatitis, or contact dermatitis driving the itch
- Patients without behavioral intervention for habit scratching
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Qué preguntar a su clínico
- Has the underlying cause of itch (atopic dermatitis, contact allergy, psoriasis, anxiety) been identified?
- Have I tried potent topical corticosteroid under occlusion?
- Have I been offered habit-reversal training, gabapentin, or an SSRI?
- What is the risk that new bite sites become scratch targets?
- What is the published evidence base for leeches in LSC?
- How will the scratch-itch cycle be addressed alongside any leech sessions?
- Cuándo buscar atención urgente
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Severe spreading infection of scratched skin
- New systemic symptoms of itch (weight loss, lymphadenopathy)
Qué NO significa esto
- It does not mean leech therapy is FDA-cleared for LSC — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace potent topical corticosteroid or behavioral therapy.
- It does not address the scratch-itch cycle.
- It does not identify or treat underlying causes of itch.
- It does not have controlled-trial evidence in LSC.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- dermatological
- ICD-10
- L28.0, L28.1, L28.2
- Safety tier
- medium
Evidence Summary
Lichen simplex chronicus is lichenified, hyperpigmented, well-circumscribed plaques caused by chronic mechanical scratching or rubbing, often initiated by underlying pruritus (atopic dermatitis, neuropathic itch, anxiety). Evidence-based management focuses on breaking the itch-scratch cycle: high-potency topical corticosteroids (clobetasol, halobetasol) under occlusion, intralesional triamcinolone for refractory plaques, topical calcineurin inhibitors as steroid-sparing agents, oral antihistamines, treatment of underlying anxiety or atopy, and behavioral interventions (habit reversal). No published controlled trials of hirudotherapy exist for lichen simplex chronicus. Placement on the lichenified plaque is contraindicated; the mechanical disruption may temporarily relieve the itch but will likely re-initiate the scratch cycle.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Placement directly on lichenified plaque (absolute)
- Untreated underlying pruritus etiology (atopy, neuropathic, anxiety)
- Suspected superinfection at plaque site
- Genital, perianal, or scalp lichen simplex (specialist only)
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.